Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET
Sponsor: OHSU Knight Cancer Institute
Summary
The purpose of this prospective cohort study is to investigate the role of Fluciclovine Positron Emission Tomography (PET) in patients with biochemical recurrence of prostate cancer (BCR) and a negative Prostate Specific Membrane Antigen (PSMA) PET, specifically, whether Fluciclovine PET can help detect local recurrence and whether the results of Fluciclovine PET can change management.
Official title: Prospective Study Evaluating the Role of Axumin® (Fluciclovine or 18F-FACBC) PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET
Key Details
Gender
MALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2023-10-04
Completion Date
2026-12-01
Last Updated
2025-11-14
Healthy Volunteers
No
Conditions
Interventions
Fluciclovine PET/CT
8 mCi (± 20%) of Fluciclovine administered as a bolus intravenous injection
Locations (1)
Oregon Health & Science University
Portland, Oregon, United States